Uses of Invinorax 300

Invinorax 300 is on the list of essential medicines of the World Health Organization, belonging to the group of drugs against infections, parasites, antivirals and fungi. This is a medicine used to treat chronic hepatitis B and HIV/AIDS.

Invinorax 300 has the main ingredient Tenofovir disoproxil fumarate 300mg, the drug is commonly used in the following cases:
In the treatment of hepatitis B : Tenofovir Disoproxil Fumarate is used to treat chronic hepatitis B in humans adults with compensated liver disease, in active viral phase or with persistently elevated serum alanine aminotransferase (ALT) levels. Tenofovir can be used to prevent HIV in people who are at high risk of getting a sexually transmitted infection or injecting drug use. Tenofovir Disoproxil Fumarate Tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults over 18 years of age.

Usage :
For HIV-1 infection, Tenofovir is indicated in combination with other antiretroviral drugs for people 2 years of age and older. For patients with chronic hepatitis B, the drug is indicated for patients 12 years of age and older. The drug is produced in the form of film-coated tablets, used orally. If the patient feels that the medicine is difficult to swallow, the drug can be dissolved with 100 ml of filtered water or orange juice before use. Drink after meals. Dosage:
The usual applied dose in the treatment of HIV or chronic hepatitis B is 1 tablet x 1 time/day. Dosage in patients with renal failure should be adjusted according to the degree of creatinine clearance. Specifically as follows:
Mild renal impairment with creatinine clearance 50 - 80ml/min using Tenofovir Disoproxil Fumarate dose once/day. Moderate renal impairment with creatinine clearance 30 - 49 ml/min using 1 tablet of Tenofovir Disoproxil Fumarate (300 mg) 48 hours apart Severe renal impairment with creatinine clearance < 30 ml/min and patients on hemodialysis: Doctor Doctors recommend not using the drug in these cases. For patients with hepatic impairment: No dosage adjustment is required. Note:
In the treatment of chronic hepatitis B: For HBeAg+ patients without cirrhosis, treatment should be continued for at least 6-12 months after seroconversion has been determined. HBe. To ensure that there is no recurrence of hepatitis B virus, patients should monitor ALT and HBV DNA levels regularly after stopping treatment. Patients with renal impairment: In patients with renal impairment, tenofovir is excreted by the kidneys and tenofovir concentrations may be increased. Therefore, drugs should only be used for patients when absolutely necessary. In the event that Tenofovir Disoproxil Fumarate is discontinued in HIV-infected or co-infected chronic hepatitis B patients, these patients should be closely monitored, as there have been reports of severe progressive liver disease. more important in these subjects. Contraindications:
The drug is not recommended for patients who are sensitive or allergic to Tenofovir. Do not use the drug in patients with hypersensitivity to any of the ingredients in the drug. It should not be used in patients with end-stage renal failure (creatinine clearance less than 15 mL/min).

Common side effects such as: Hypophosphatemia, abdominal pain, nausea, vomiting, diarrhea, dizziness, flatulence. The proportion of patients who had to stop using the drug due to adverse effects on the gastrointestinal tract, increased ALT, and fatigue was about 1%. When combined with antiretroviral drugs, side effects such as metabolic abnormalities such as hypertriglyceridemia, hyperglycemia and lactic acidosis, hypercholesterolemia, insulin resistance, and lipid dystrophy have been reported in HIV patients including regional fat. Peripheral and subcutaneous, increased abdominal and visceral fat, mammary gland enlargement, hypertonia, peripheral nerve damage. Long-term use of tenofovir disoproxil has been associated with nephrotoxicity and bone necrosis. Specifically with manifestations of nephrotoxicity may appear as Fanconi syndrome, acute kidney injury or impaired glomerular filtration rate. Some undesirable effects may occur but are very rare such as: Shortness of breath, lactic acidosis, pancreatitis, increased transaminases, hepatitis, rash, acute renal failure, renal failure, Fanconi's syndrome, increased creatinine, Acute tubular necrosis, asthenia.

Careful use of the drug for patients with renal dysfunction, due to impaired renal function affecting the kidney's ability to eliminate, it is necessary to adjust the dose of the drug to suit the patient's condition. .
Patients should be careful not to stop taking the drug or increase the dose on their own because this can make the condition not only not improve but also can lead to serious complications such as cirrhosis of the liver, cancer liver letter.
Patients should use the drug regularly throughout the course of treatment, use the right dose and at the right time so that the drug concentration in the body is always at the therapeutic threshold and promotes the best antiviral effect.
For pregnant or lactating women: The drug is likely to be excreted in human milk as metabolites. Therefore, it can affect the fetus and newborn. Therefore, when using drugs with the above cases, it is necessary to weigh the benefits and harms of the drug.

When co-administered with Darunavir or Ritonavir: Invinorax 300 increased tenofovir AUC by 22%, Cmin by 37%. Renal function should be monitored during administration. Drugs that are eliminated by the renal route: Since Invinorax 300 is mainly eliminated by the kidneys, the concomitant use of drugs containing Tenofovir Disoproxil Fumarate with drugs that are excreted by the kidneys. will impair renal function or compete for active tubular secretion. Atazanavir : Taking these two drugs together resulted in a 25% decrease in area under the curve (AUC), a 28% decrease in maximum concentration (Cmax) and a 26% decrease in minimum concentration (Cmin). Tenofovir: AUC increased by 37%, Cmax increased by 34%, Cmin increased by 29%. Co-administration with Lopinavir and Ritonavir: Increases tenofovir AUC by 32%, Cmin by 51%. Renal function should be monitored during drug administration. Nephrotoxic drugs: Concomitant use of Tenofovir Disoproxil Fumarate with nephrotoxic drugs such as aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2 must be avoided. Tacrolimus: Concomitant use with Invinorax 300 affects kidney function. Didanosine: Co-administration of Tenofovir Disoproxil Fumarate with Didanosine causes a 40-60% increase in didanosine concentrations, which may lead to increased undesirable effects. Above is all information about the uses, doses and precautions when using Invinorax 300. To ensure safety for health and maximize the effectiveness of treatment, patients need to take Invinorax 300 exactly as directed by their doctor.